TAGRISSO (osimertinib tablets) Patient Assistance Program
Don’t let the high cost of brand third-generation EGFR TKI disrupt your EGFR-mutated non-small cell lung cancer treatment. We help eligible patients access Tagrisso (osimertinib tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Tagrisso (osimertinib) is FDA-approved for first-line treatment of metastatic EGFR exon 19 deletion or exon 21 L858R-mutated NSCLC, as adjuvant therapy after tumor resection in EGFR exon 19 deletion or L858R-mutated NSCLC, for metastatic EGFR T790M-mutated NSCLC (after prior EGFR TKI), and in combination with chemotherapy for first-line metastatic EGFR-mutated NSCLC. Third-generation EGFR tyrosine kinase inhibitor — selective for EGFR-activating mutations and the T790M resistance mutation while sparing wild-type EGFR.
- Without assistance, Tagrisso costs commonly run approximately $17,000–$20,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Tagrisso for a flat $69.95 per month.
- Other EGFR TKIs (older, less effective for common-mutation EGFR or T790M-resistant disease): erlotinib (Tarceva — generic), gefitinib (Iressa — generic), afatinib (Gilotrif), dacomitinib (Vizimpro), mobocertinib (Exkivity — withdrawn 2023 for exon 20 ins). For EGFR exon 20 insertions specifically: Rybrevant (amivantamab — bispecific EGFR-MET) ± Lazcluze (lazertinib), with chemotherapy backbones. For ALK rearrangement: alectinib (Alecensa), lorlatinib (Lorbrena), brigatinib (Alunbrig), ceritinib (Zykadia), crizotinib (Xalkori). For ROS1: entrectinib (Rozlytrek), crizotinib, lorlatinib, repotrectinib (Augtyro). For BRAF V600E: dabrafenib + trametinib (Tafinlar + Mekinist). For other oncogenes: capmatinib, tepotinib (MET exon 14 skip), trastuzumab deruxtecan (Enhertu — HER2), selpercatinib/pralsetinib (RET), KRAS G12C inhibitors (Lumakras, Krazati). Tumor molecular profiling essential for treatment selection.
What is Tagrisso Prescription Assistance Program?
The Tagrisso Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Tagrisso (used for EGFR-mutated non-small cell lung cancer) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, oncology coordination, EGFR mutation documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing lung cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Tagrisso PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation (typically including tumor EGFR mutation testing results, prior treatment history, and indication-specific clinical criteria), follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Tagrisso targeted therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Tagrisso enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your lung cancer treatment.
Pharmacy Price Comparison
- Without assistance, Tagrisso costs thousands of dollars per month at specialty pharmacies. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted lung cancer therapy accessible if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Tagrisso advocacy service:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$19,500/mo | Save ~$17,680/mo |
| CVS Specialty | ~$20,000/mo | Save ~$17,730/mo |
| Walmart | ~$17,700.00 | Save ~$17,630/mo |
| Specialty pharmacy | ~$17,500/mo | Save ~$17,650/mo |
| Generic erlotinib (alt EGFR TKI) | ~$200/mo | Generic older TKI alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Tagrisso — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Tagrisso Prescription Program ?
When you’re battling lung cancer and your oncologist prescribes Tagrisso because genetic testing confirmed your tumor’s EGFR mutation, the administrative complexity of accessing a $17,746-per-month specialty medication should not add to your burden. Insurance prior authorizations, specialty pharmacy coordination, copay assistance enrollment, and annual re-enrollment all demand time and energy during the most challenging period of your life.
Our trained Patient Advocates specialize in oncology medication access and manage every administrative detail on your behalf. From the moment you enroll, your advocate prepares your application, coordinates with your oncologist to gather required medical documentation (including EGFR mutation test results), submits everything to the appropriate program, and tracks your status through every stage. When your medication is due for refill, they coordinate with your specialty pharmacy proactively.
Our pricing is simple and predictable: $69.95 per month — every month. While the medication itself is provided at no cost through the manufacturer’s program, our monthly fee covers all advocacy, application management, oncologist coordination, and specialty pharmacy oversight. If we’re unable to secure access, you won’t be charged.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Tagrisso:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $17,000–$20,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Tagrisso assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Tagrisso Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Tagrisso:
Tagrisso is a third-generation EGFR tyrosine kinase inhibitor designed for high selectivity to EGFR-activating mutations (exon 19 deletion, L858R) and the T790M resistance mutation that drives resistance to older EGFR TKIs (erlotinib, gefitinib, afatinib). Its selectivity for mutant vs wild-type EGFR translates to better tolerability — less skin rash and diarrhea — than older TKIs. The FLAURA trial established Tagrisso as superior to erlotinib/gefitinib for first-line common-mutation EGFR NSCLC.
How Tagrisso works:
EGFR (epidermal growth factor receptor) drives tumor growth in EGFR-mutated non-small cell lung cancer. Common EGFR mutations (exon 19 deletion, exon 21 L858R) are typically sensitive to EGFR TKI therapy. The T790M mutation emerges as a resistance mechanism in approximately 50–60% of patients progressing on older EGFR TKIs.
Osimertinib covalently binds and irreversibly inhibits mutant EGFR (exon 19 del, L858R, T790M) while sparing wild-type EGFR. Better CNS penetration vs older TKIs — particularly valuable since brain metastases are common in EGFR-mutated NSCLC. The FLAURA trial demonstrated superior overall survival vs erlotinib/gefitinib in first-line common-mutation EGFR NSCLC. ADAURA established benefit in adjuvant setting after surgery. FLAURA2 demonstrated added benefit of chemotherapy combination.
Form and use:
Tagrisso 40 mg or 80 mg tablets. Typical dose 80 mg once daily. Take with or without food. Continue until disease progression or unacceptable toxicity. Hold for grade 3+ toxicity. Adjuvant treatment course is up to 3 years. Periodic ECG (QT interval), CBC, comprehensive metabolic panel, and ejection fraction monitoring as clinically indicated.
Generic availability:
No generic Tagrisso. Other EGFR TKIs (mostly with generics in some markets — older, less effective for common-mutation EGFR or T790M-resistant disease): erlotinib (Tarceva — generic), gefitinib (Iressa — generic), afatinib (Gilotrif — generic in some markets), dacomitinib (Vizimpro — brand). For EGFR exon 20 insertions: Rybrevant (amivantamab — bispecific EGFR-MET, IV/SC) ± Lazcluze (lazertinib — combination for first-line common-mutation EGFR NSCLC), with chemotherapy backbones (carboplatin + pemetrexed). For ALK rearrangement: alectinib, lorlatinib, brigatinib, ceritinib, crizotinib. For ROS1: entrectinib, crizotinib, lorlatinib, repotrectinib (Augtyro). For BRAF V600E: dabrafenib + trametinib. For other oncogenes: capmatinib, tepotinib (MET exon 14 skip), trastuzumab deruxtecan (Enhertu — HER2), selpercatinib/pralsetinib (RET), KRAS G12C inhibitors. For wild-type or untestable NSCLC: pembrolizumab (Keytruda) ± chemotherapy, nivolumab + ipilimumab combinations, atezolizumab, durvalumab. Tumor or liquid biopsy molecular profiling essential. NCCN guidelines guide treatment selection.
Warnings:
**Interstitial lung disease and pneumonitis (sometimes fatal — evaluate any new respiratory symptoms), QTc prolongation (monitor ECG, electrolytes; avoid additional QT-prolonging drugs), cardiomyopathy and decreased ejection fraction (monitor LVEF at baseline and periodically), keratitis and cutaneous vasculitis (rare).** Other: rash, diarrhea, dry skin, paronychia, fatigue, decreased appetite, stomatitis, decreased weight, cytopenias, hepatotoxicity. Embryo-fetal toxicity. Drug interactions: strong CYP3A4 inhibitors (azoles, clarithromycin, ritonavir, grapefruit) increase osimertinib — caution; strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) reduce efficacy — avoid.
FAQ (Frequently Asked Questions)
How Much Does Tagrisso Cost Without Insurance?
$17,000–$20,000 per month. Annual cost exceeds $200,000 without assistance. Specialty pharmacy and Patient Assistance Programs are essential for most patients to access this targeted lung cancer therapy.
Is Tagrisso considered chemotherapy?
No — Tagrisso is a targeted oral therapy (third-generation EGFR tyrosine kinase inhibitor) — not traditional cytotoxic chemotherapy. Different toxicity profile from chemotherapy with generally better tolerability.
Why is EGFR mutation testing required before starting Tagrisso?
Tagrisso is specifically active against EGFR-mutated NSCLC (exon 19 deletion, L858R, T790M). Tumor or liquid biopsy molecular testing identifies patients who will benefit. NCCN guidelines recommend comprehensive biomarker testing (EGFR, ALK, ROS1, BRAF, KRAS, NTRK, RET, MET, HER2, PD-L1) for all metastatic non-squamous NSCLC to guide treatment selection.
What is the difference between Tagrisso, erlotinib (Tarceva), and gefitinib (Iressa)?
All target EGFR-activating mutations. Tagrisso (osimertinib) is third-generation — superior overall survival in FLAURA, better CNS penetration, less skin/GI toxicity, active against T790M resistance mutation. Erlotinib and gefitinib are older generations with generic versions available (much cheaper) but inferior outcomes in first-line common-mutation EGFR NSCLC. Tagrisso is now standard first-line; older TKIs primarily used in specific clinical situations or where Tagrisso is not available.
What is the difference between Tagrisso and Rybrevant for EGFR-mutated lung cancer?
Different mechanisms and indications. Tagrisso is a small-molecule oral EGFR TKI for common-mutation (exon 19 del, L858R) and T790M-mutated NSCLC. Rybrevant is a bispecific EGFR-MET antibody injection/IV for EGFR exon 20 insertion-mutated NSCLC (a subtype not well-treated by standard EGFR TKIs) and in combination with lazertinib for common-mutation first-line NSCLC. EGFR mutation subtype determines choice.
How does Tagrisso help with brain metastases?
Brain metastases are common in EGFR-mutated NSCLC. Tagrisso has better blood-brain barrier penetration than older EGFR TKIs (erlotinib, gefitinib, afatinib) — providing meaningful intracranial activity. The FLAURA trial demonstrated improved CNS progression-free survival vs erlotinib/gefitinib. Brain MRI is appropriate at baseline and periodically.
What are the most common Tagrisso side effects?
Rash (less than older TKIs), diarrhea, dry skin, paronychia (nail bed inflammation), fatigue, stomatitis. Less common but serious: pneumonitis (ILD — sometimes fatal), QT prolongation, decreased ejection fraction. Monitor with periodic ECG, CBC, and clinical assessment for respiratory symptoms.
What happens if my Tagrisso Patient Assistance Program application is denied?
We help explore manufacturer copay programs for commercial insurance, Lung Cancer Research Foundation, Patient Access Network, Patient Advocate Foundation, CancerCare, LUNGevity Foundation, generic erlotinib or gefitinib as alternative EGFR TKIs (substantially cheaper but inferior outcomes in first-line common-mutation EGFR NSCLC), platinum-based chemotherapy combinations, and Medicare Part D Extra Help and state SPAP programs.
Take Control of Your Medication Costs
Targeted therapy for EGFR-mutated lung cancer should not be derailed by cost. Tagrisso is the established first-line standard for common-mutation EGFR NSCLC with superior outcomes vs older TKIs. Our Tagrisso advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Tagrisso through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.